Company intelligence
Ocular Therapeutix, Inc.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across drug development, treatment, and outcomes. AXPAXLI™ (also known as OTX-TKI), an investigational axitinib hydrogel administered by intravitreal injection, is Ocular’s leading investigational candidate for retinal disease, based on its proprietary ELUTYX™ technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and has potential applications across other retinal diseases such as non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME).
Verified activity
Signals from Ocular Therapeutix, Inc.
7 published signals
Presence & Recognition
Ocular Therapeutix, Inc. attended the Asia-Pacific Vitreo-retina Society symposium where Chief Development Officer Peter Kaiser, MD, explored the mechanisms of action of different classes of anti-VEGF therapies and wet age-related macular degeneration.
Reported by Ocular Therapeutix, Inc.
Research & Knowledge
Ocular Therapeutix, Inc. is working to reduce treatment burden for patients requiring anti-VEGF injections for wet AMD, aiming to preserve vision for the long term.
Reported by Ocular Therapeutix, Inc.
Presence & Recognition
Ocular Therapeutix, Inc. participated in the Asia-Pacific Vitreo-retina Society symposium where Adnan Tufail, MBBS, MD, explained how baseline visual acuity influences trial outcomes in wet age-related macular degeneration.
Reported by Ocular Therapeutix, Inc.
Research & Knowledge
Ocular Therapeutix, Inc. highlighted the importance of generating rigorous, clinically meaningful evidence through its SOL program design.
Reported by Pravin Dugel
Presence & Recognition
Ocular Therapeutix, Inc. participated in the 19th Asia-Pacific Vitreo-retina Society Congress on the Gold Coast to discuss durability and sustained disease control in wet age-related macular degeneration.
Reported by Ocular Therapeutix, Inc.
Research & Knowledge
Ocular Therapeutix, Inc. followed the FDA guidance on trial conduct in wet age-related macular degeneration (AMD) for the design of SOL-1.
Reported by Ocular Therapeutix, Inc.
Research & Knowledge
Ocular Therapeutix, Inc. published a conversation with Biren Amin and Piper Sandler detailing the rationale behind the design of the SOL program.
Reported by Pravin Dugel